A review on antibody of aducanumab- reduces the progression of Alzheimer disease

Abstract

Alzheimer's disease which is the most common form of dementia and affecting millions of people, including family members who act as caretakers. This harmful disease is believed to account for 8% of total US healthcare spending, with health care workers costs amounting to approximately $29 billion. Alzheimer. The initial monoclonal antibody, to newly receive US FDA accelerated approval as moderate Alzheimer disease is aducanumab. Future therapies could be the first chemical approved to treat AD since 2003. The amyloid (A) pathway is becoming involved in the toxic of Alzheimer disease as it has evolved over time from a pathogen to a disease. - Biological structure. The approval of aducanumab is based on the reduction of the Amyload in the brain, which serves as a direct label for this signaling pathway. The fully human IgG1 monoclonal antibody aducanumab (BIIB-037) specifically binds to aggregated form A, inhibiting its matrix function and helping to clear plaque. There are three human trials that ended prematurely. Epidemiology, pathophysiology, and risk factors are discussed in this review, and presently aducanumab is the only drug approved for FDA that slows disease progression.